| | By Eric Sagonowsky,Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy The unrelenting churning of time means many things to many people. For pharma executives, it’s a constant reminder of the need for new launches to supplant old meds. |
|
|
|
By Zoey Becker The drug is the first weight loss treatment to win FDA approval to reduce the risk of severe cardiovascular outcomes, giving it an edge over rival Zepbound from Eli Lilly. |
By Max Bayer Merck is signing onto a new research and licensing deal with Pearl Bio, offering up to $1 billion in biobucks. The biotech is looking at fusing synthetic chemistry with biologics, broadening its therapeutic capabilities. |
By Nick Paul Taylor Eli Lilly is biting the hands that fed the weight-loss hype machine, calling out people who use the jabs to fit in a smaller dress or tuxedo in one ad and emphasizing that “obesity is a matter of health” in a second TV spot. |
By Helen Floersh A new paper in Nature Biotechnology offers the first in-depth look at how Insilico Medicine used artificial intelligence to discover, develop and test its lead drug candidate. |
By Kevin Dunleavy After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza. |
By Annalee Armstrong Eli Lilly’s donanemab has been delayed at the FDA for approval in Alzheimer’s disease, a blow to the company’s efforts to get what could be a $2.8 billion per year opportunity by 2028. |
By Eric Sagonowsky As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C. |
By Conor Hale At the International Conference on Advanced Technologies and Treatments for Diabetes, being held this week in Florence, Italy, the company put forward the first accuracy data for its new Accu-Chek SmartGuide sensor and apps. |
By Kevin Dunleavy Automated cell therapy manufacturing pioneer Cellares has hit a key milestone, gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is the size of a truck and is designed to boost production while reducing costs and failure rates. |
By Max Bayer In 2022, the highest-paid R&D executive made $12.2 million. John Reed, M.D., Ph.D., of Johnson & Johnson is telling the rest of the field to hold his beaker. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Wednesday, March 20, 2024 | 1pm ET / 10am PT Join us as we take a deep dive into how to plan and manage the evolution of your eTMF. This webinar will feature case studies from leading industry organizations, the latest best practices and TMF trends, data standards and migration considerations, and more. Register now.
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| WhitepaperAmidst rapid change, it is crucial for specialty distributors to maintain a balance of service and quality for manufacturers, ensuring neither is sacrificed. Explore why this balance is paramount for success in the evolving landscape of pharma. Sponsored by: BioCare |
| |
|
